ConductScience.org, home

Paper34072068

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.

Martino M and 16 others. Cancers (Basel), 2021. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. Papers, record 34072068. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34072068

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
1.5
iCite
Revised in PubMed
2023-09-20
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Martino MMassimohttps://orcid.org/0000-0002-3987-419X
2Canale FAFilippo Antonio
3Alati CCaterina
4Vincelli IDIolanda Donatella
5Moscato TTiziana
6Porto GGaetana
7Loteta BBarbara
8Naso VVirginia
9Mazza MMassimilianohttps://orcid.org/0000-0001-9053-5743
10Nicolini FFabio
11Ghelli Luserna di Rorà AAndrea
12Simonetti GGiorgiahttps://orcid.org/0000-0001-6954-969X
13Ronconi SSonia
14Ceccolini MMichela
15Musuraca GGerardo
16Martinelli GGiovannihttps://orcid.org/0000-0002-1025-4210
17Cerchione CClaudiohttps://orcid.org/0000-0002-9104-5436

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133321731The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma.Pharmaceuticals (Basel)2020https://conductscience.org/library/papers/33321731PubMed
232961764Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma.J Clin Med2020https://conductscience.org/library/papers/32961764PubMed
332729730Antibody-drug conjugates for multiple myeloma.Expert Opin Biol Ther2021https://conductscience.org/library/papers/32729730PubMed
433275747Future of CAR T cells in multiple myeloma.Hematology Am Soc Hematol Educ Program2020https://conductscience.org/library/papers/33275747PubMed
532989217Multiple myeloma current treatment algorithms.Blood Cancer J2020https://conductscience.org/library/papers/32989217PubMed
633303615Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.Science2020https://conductscience.org/library/papers/33303615PubMed
733089218Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma.Blood Cancer Discov2020https://conductscience.org/library/papers/33089218PubMed
833368165Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy.Br J Haematol2021https://conductscience.org/library/papers/33368165PubMed
923344265B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.Clin Cancer Res2013https://conductscience.org/library/papers/23344265PubMed
1029605883
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia.
Cancer Immunol Immunother2018https://conductscience.org/library/papers/29605883PubMed
1132221812Memory T cells: strategies for optimizing tumor immunotherapy.Protein Cell2020https://conductscience.org/library/papers/32221812PubMed
1233285522Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2020https://conductscience.org/library/papers/33285522PubMed
1332516895BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.Cancers (Basel)2020https://conductscience.org/library/papers/32516895PubMed
1433227097T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.Oncotarget2020https://conductscience.org/library/papers/33227097PubMed
1528361085Human stem memory T cells (TSCM) as critical players in the long-term persistence of immune responses.Ann Transl Med2017https://conductscience.org/library/papers/28361085PubMed
1632943087BCMA-targeted immunotherapy for multiple myeloma.J Hematol Oncol2020https://conductscience.org/library/papers/32943087PubMed
1733272302Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.J Hematol Oncol2020https://conductscience.org/library/papers/33272302PubMed
1833383757The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma.Pharmaceuticals (Basel)2020https://conductscience.org/library/papers/33383757PubMed
1932875817Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.Future Oncol2020https://conductscience.org/library/papers/32875817PubMed
2028928126Chimeric antigen receptor T-cell therapies for multiple myeloma.Blood2017https://conductscience.org/library/papers/28928126PubMed

See all 42 referencesDownload CSV of references

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
42662940The landscape and trajectory of global CRISPR therapeutics.Mol Ther Nucleic Acids2026https://conductscience.org/library/papers/42662940PubMed
42375474Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics.Mol Ther Adv2026https://conductscience.org/library/papers/42375474PubMed
42345736Quality of Life in CAR-T Cell Therapy.Hematol Rep2026https://conductscience.org/library/papers/42345736PubMed
41335261Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application.Mol Biol Rep2025https://conductscience.org/library/papers/41335261PubMed
41283232The Gut Microbiome Role in Multiple Myeloma: Emerging Insights and Therapeutic Opportunities.Hematol Rep2025https://conductscience.org/library/papers/41283232PubMed
40304075Prognostic and biological characteristics associated with multiple myeloma presenting only with anemia.Haematologica2025https://conductscience.org/library/papers/40304075PubMed
39844764The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy.Haematologica2025https://conductscience.org/library/papers/39844764PubMed
39502704Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy.Front Immunol2024https://conductscience.org/library/papers/39502704PubMed
39313307BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple Myeloma.J Immunother Cancer2024https://conductscience.org/library/papers/39313307PubMed
39130943Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review.Cureus2024https://conductscience.org/library/papers/39130943PubMed
39091493CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects.Front Immunol2024https://conductscience.org/library/papers/39091493PubMed
38862983Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy.Cell Commun Signal2024https://conductscience.org/library/papers/38862983PubMed
38756776Effectiveness of CAR-T treatment toward the potential risk of second malignancies.Front Immunol2024https://conductscience.org/library/papers/38756776PubMed
38672686Immune Therapies in AL Amyloidosis-A Glimpse to the Future.Cancers (Basel)2024https://conductscience.org/library/papers/38672686PubMed
38616952Educational Case: Multiple myeloma.Acad Pathol2024https://conductscience.org/library/papers/38616952PubMed
38152777Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-cell Therapy: A Retrospective Study Analyzing Risks, Outcomes, and Healthcare Burden.Cureus2023https://conductscience.org/library/papers/38152777PubMed
37668832Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.Int J Hematol2023https://conductscience.org/library/papers/37668832PubMed
37569693CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.Int J Mol Sci2023https://conductscience.org/library/papers/37569693PubMed
37296856Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy.Cancers (Basel)2023https://conductscience.org/library/papers/37296856PubMed
36612152How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma.Cancers (Basel)2022https://conductscience.org/library/papers/36612152PubMed

See all 27 cited byDownload CSV of cited by

Genes21

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CARS1833PubTator's text mininghttps://conductscience.org/library/genes/833NCBI Gene
CARTPT9607PubTator's text mininghttps://conductscience.org/library/genes/9607NCBI Gene
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD247919PubTator's text mininghttps://conductscience.org/library/genes/919NCBI Gene
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD521043PubTator's text mininghttps://conductscience.org/library/genes/1043NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
FASTK10922PubTator's text mininghttps://conductscience.org/library/genes/10922NCBI Gene
GPRC5D55507PubTator's text mininghttps://conductscience.org/library/genes/55507NCBI Gene
KLRK122914PubTator's text mininghttps://conductscience.org/library/genes/22914NCBI Gene
LY94063PubTator's text mininghttps://conductscience.org/library/genes/4063NCBI Gene
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970NCBI Gene
NR1I422817PubTator's text mininghttps://conductscience.org/library/genes/22817NCBI Gene
SCFV652070PubTator's text mininghttps://conductscience.org/library/genes/652070NCBI Gene
SDC16382PubTator's text mininghttps://conductscience.org/library/genes/6382NCBI Gene
SLAMF757823PubTator's text mininghttps://conductscience.org/library/genes/57823NCBI Gene
TNFRSF17608PubTator's text mininghttps://conductscience.org/library/genes/608NCBI Gene
TNFRSF93604PubTator's text mininghttps://conductscience.org/library/genes/3604NCBI Gene
TRA6955PubTator's text mininghttps://conductscience.org/library/genes/6955NCBI Gene

See all 21 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34072068

GET https://conductscience.org/api/papers/v1/34072068/references?page=2